The EU GMO Framework Is Slowing Down Gene Therapy. Here's What Regulatory Affairs Teams Need to Do About It.

You've secured your CTA. Your trial is designed. Your sites are ready.

Then the GMO clock starts — and suddenly you're looking at up to 12 months of additional review before a single patient can be treated.

If you work in regulatory affairs for gene therapy medicinal products (GTMPs), this is not a hypothetical. It's a recurring reality that continues to delay access to potentially curative therapies for patients with serious unmet medical needs.

Here's a clear-eyed breakdown of where the framework stands today — and what you can do to navigate it more effectively.

Drop your email to access the full dashboard and stay in control of your GTMP timelines.